序号 |
标题 |
次数 |
作者 |
发布时间 |
63181 |
cas:159857-79-1,Val-cit-PAB-OH,ADC定制 |
56 |
wyh |
2024-12-18 |
63182 |
双载IR780与HCQ的温敏脂质体(IR780/HCQ-Lip) |
96 |
axc |
2024-12-18 |
63183 |
endo BCN-PEG3-Val-Cit,(1R,8S,9S)-双环[6.1.0]壬-三聚乙二醇-VAL-CIT |
55 |
kx |
2024-12-18 |
63184 |
DOTA-(PEG28)2-A20FMDV2 双末端聚乙二醇化的A20FMDV2偶联DOTA大环配体 |
67 |
h |
2024-12-18 |
63185 |
PEG2K-Hyd-PEI聚合物包裹共载SS31肽和胰岛素的脂质体纳米粒,PHP-DPS@INS,NPs |
77 |
axc |
2024-12-18 |
63186 |
cas:2226472-28-0 ,DBCO-PEG4-Val-Cit-PAB-PNP,二苯并环辛炔-四聚乙二醇-VAL-CIT-PAB-PNP 酯 |
67 |
kx |
2024-12-18 |
63187 |
FA-PEG-DOTA 叶酸-聚乙二醇-DOTA |
53 |
h |
2024-12-18 |
63188 |
OA-PEG5烷基链定制 |
83 |
zyl |
2024-12-18 |
63189 |
共载SS31肽和胰岛素的脂质体纳米粒,DPS@INS,NPs,脂质体纳米载体定制服务 |
85 |
axc |
2024-12-18 |
63190 |
DOTA-PEG27-Cys-VS |
57 |
h |
2024-12-18 |
63191 |
cas:1613321-01-9 ,6-Azidohexanoyl-Val-Cit-PAB,6-叠氮己酰-VAL-CIT-PAB |
53 |
kx |
2024-12-18 |
63192 |
MPA-PEG4-GB-6的功能与应用 |
87 |
zyl |
2024-12-18 |
63193 |
DOTA-PEG-GA DOTA-聚乙二醇-甘草次酸 |
56 |
h |
2024-12-18 |
63194 |
负载吡非尼酮的肺靶向纳米脂质体,GALA-PFD-Lip,多功能载药脂质体定制服务 |
110 |
axc |
2024-12-18 |
63195 |
PAMAM-PG-g-s-s-DOTA(Gd)+FA 纳米球状MRI造影剂 |
65 |
h |
2024-12-18 |
63196 |
DBCO-Val-Cit-PAB-MMAE,二苯并环辛炔-VAL-CIT-PAB-MMAE |
49 |
kx |
2024-12-18 |
63197 |
脂质体包裹噬菌体ABSZ6(LIP-ABSZ6),载药脂质体定制服务 |
164 |
axc |
2024-12-18 |
63198 |
DOTA-3G3-dimer DOTA-3G3-二聚体 |
59 |
h |
2024-12-18 |
63199 |
CAS: 1884578-27-1 Alloc-Val-Ala-PAB-PNP |
65 |
WYQ |
2024-12-18 |
63200 |
cas:646502-53-6 ,MC-Val-Cit-PAB-MMAE,VCMMAE 单甲基奥瑞他汀E |
76 |
kx |
2024-12-18 |
63201 |
布地奈德脂质体,Budesonide,liposomes,BUD-LNPs,靶向脂质体定制服务 |
76 |
axc |
2024-12-18 |
63202 |
DOTA-Lys-PEG4-[D-Phe6,Sta13]-BN(6-14)NH2(HZ219)DOTA缀合的GRPr拮抗剂 |
60 |
h |
2024-12-18 |
63203 |
[131I]SIB-PEG4-CHC 聚乙二醇化秋水仙素衍生物-定制 |
90 |
zyl |
2024-12-18 |
63204 |
PEG-G5.NH2-FITC-DOTA(Gd)-Monalizumab/IPH4301纳米探针 |
53 |
h |
2024-12-18 |
63205 |
虾青素脂质体,提供荧光脂质体定制服务 |
80 |
axc |
2024-12-18 |
63206 |
PEG2-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2;peg2-RM26-科研定制 |
110 |
zyl |
2024-12-18 |
63207 |
DOTA-PEG(4)-[D-Phe(6) |
57 |
h |
2024-12-18 |
63208 |
Azide-PEG3-Val-Cit-PAB-MMAF,叠氮-三聚乙二醇-VAL-CIT-PAB-MMAF |
55 |
kx |
2024-12-18 |
63209 |
DOTA-3G(3)-dimer DOTA-3G(3)-二聚体 |
77 |
h |
2024-12-18 |
63210 |
HS-(CH2)11-triphenylimidazole;HS-(CH2)11-三苯基咪唑 |
81 |
zyl |
2024-12-18 |
63211 |
雷公藤甲素脂质体,1-Lips,脂质体纳米载体定制服务 |
71 |
axc |
2024-12-18 |
63212 |
DOTAGA-PEG(2)-RM26 DOTA修饰铃蟾肽衍生的GRPR拮抗剂PEG(2)-RM26 |
78 |
h |
2024-12-18 |
63213 |
cas:159857-79-1,Val-Cit-PAB,ADC定制 |
51 |
wyh |
2024-12-18 |
63214 |
2529982-76-9,Azido-PEG4-Val-Ala-PAB,叠氮-四聚乙二醇-VAL-ALA-PAB |
64 |
kx |
2024-12-18 |
63215 |
DOTA-PEG11-Tz DOTA-PEG11-四嗪 |
83 |
h |
2024-12-18 |
63216 |
阿霉素-卡铂脂质体,doxorubicin-carboplatin,liposome,DOX/CBP-Lip,多功能载药脂质体定制服务 |
65 |
axc |
2024-12-18 |
63217 |
HS(CH2)11OH烷基链定制 |
67 |
zyl |
2024-12-18 |
63218 |
NH(2)-PEG-DOTA-PEG-NH(2)-GQDs NH2-PEG-DOTA-PEG-NH2偶联羧基化石墨烯量子点 |
79 |
h |
2024-12-18 |
63219 |
Fmoc-Val-Cit-PAB-PNP(CAS:863971-53-3) |
54 |
WYQ |
2024-12-18 |
63220 |
Au23(S-c-C6H11)16 烷基链定制 |
62 |
zyl |
2024-12-18 |
63221 |
DOTA-PEG-OPSS-AuNP 邻吡啶基二硫化物-聚乙二醇-金属螯合剂DOTA修饰30纳米金纳米粒子(AuNP) |
67 |
h |
2024-12-18 |
63222 |
壳聚糖修饰芹菜素脂质体,CS-AP-L,载药脂质体定制服务 |
84 |
axc |
2024-12-18 |
63223 |
DBCO-PEG4-Val-Ala-PAB-PNP,二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB-PNP |
51 |
kx |
2024-12-18 |
63224 |
cas:2412924-07-1,Py-MPB-amino-C3-PBD,ADC定制 |
54 |
wyh |
2024-12-18 |
63225 |
DOTA偶联胃泌素释放肽受体(GRP-R)配体 |
81 |
h |
2024-12-18 |